Chemomab Therapeutics (CMMB) Total Current Liabilities (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Total Current Liabilities data on file, last reported at $1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 54.07% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (down 54.07% YoY), and the FY2025 full-year result was $1.5 million, down 54.07% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $1.5 million, up from $1.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $7.0 million in Q1 2023 and bottomed at $1.1 million in Q3 2025.
• The 5-year median for Total Current Liabilities is $4.3 million (2024), against an average of $3.9 million.
• The widest annual swing landed in 2022, when Total Current Liabilities jumped 236.01%; it then tumbled 73.86% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $2.6 million in 2021, then jumped by 154.68% to $6.7 million in 2022, then decreased by 28.32% to $4.8 million in 2023, then slumped by 33.48% to $3.2 million in 2024, then sank by 54.07% to $1.5 million in 2025.
• The last three Total Current Liabilities figures came in at $1.5 million (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.

Peer Comparison